Business
Zuckerberg at a UFC match
Mark Zuckerberg at UFC 300 at T-Mobile Arena on April 13, 2024, in Las Vegas (Jeff Bottari/Getty Images)
Weird Money

Security spending on company CEOs is poised to skyrocket

We’ll probably see a big uptick in companies following Meta’s lead on paying for executive security in 2025.

Jack Raines

The biggest story of December has been the fatal shooting of UnitedHealthcare CEO Brian Thompson. I’m not going to comment on the ongoing investigation, but in the wake of the shooting, The Wall Street Journal published an interesting piece on company spend on executive security outside of work, citing a report from executive-intelligence provider Equilar.

The report says that 27.6% of S&P 500 companies provided security for at least one top executive, up from 23.5% in 2021, and median spending doubled to almost $100,000. (Note: these figures don’t include security spend that occurs in offices or on work travel, as those are considered normal business expenses.) Within that 27.6%, there are some strong outliers.

Meta spent $24.39 million, more than triple the next highest spender, Alphabet, which came in at $6.78 million. UnitedHealthcare, notably, didn’t have any listed costs in 2023. But after that recent shooting, security spend is poised for an uptick:

“Dozens of security chiefs from large U.S. companies met on a call Wednesday to discuss security protocols. One security adviser, Global Guardian CEO Dale Buckner, said he fielded calls from companies looking to send armed guards to accompany executives attending conferences in New York and other U.S. cities this week.”

Given risks posed by the internet, that increase in security spend is probably overdue. The internet has introduced two risk factors for known figures:

  1. It’s much, much easier to find someone’s personal information, such as where they live, what their travel itinerary might be for work events, etc.

  2. Social media is a catalyst for unrest, as it facilitates frictionless communication between individuals with similar gripes.

At any given time, any number of people can be upset about any number of things, including the climate crisis, health insurance, poorly timed layoffs, and politics. Executives of companies deemed to be tied to one of these issues often become targets of this angst, social media allows for the creation of echo chambers of like-minded individuals who share that angst, personal information on these individuals is more accessible than it was pre-internet, and it takes only one person to create a tragedy.

Given that every company in the S&P 500 is worth at least $6 billion, I’m surprised that just ~27% of companies so far have paid for additional security for company executives. I imagine that next quarter’s earnings season will show several companies adding a new line-item expense for “personal security.”

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.